We are live on
!
Find out more
SAM
Senzar Asset Management Portfolio holdings
AUM
$34.7M
1-Year Est. Return
0.56%
This Fund
S&P 500
This Quarter
Est. Return
+9.24%
1 Year Est. Return
+0.56%
3 Year Est. Return
-0.75%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$387M
AUM Growth
-$72.2M
(-16%)
Cap. Flow
-$92.9M
Cap. Flow
% of AUM
-24.01%
Top 10 Holdings %
Top 10 Hldgs %
60.3%
Holding
49
New
8
Increased
8
Reduced
19
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ESRX
Express Scripts Holding Company
ESRX
|
+$22.3M |
| 2 |
AGN
Allergan plc
AGN
|
+$14.3M |
| 3 |
Sanofi
SNY
|
+$13.3M |
| 4 |
MiMedx Group
MDXG
|
+$12.2M |
| 5 |
Viatris
VTRS
|
+$12.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$30.6M |
| 2 |
Biogen
BIIB
|
+$24.6M |
| 3 |
Amgen
AMGN
|
+$23.7M |
| 4 |
TVTY
Tivity Health, Inc. Common Stock
TVTY
|
+$21.1M |
| 5 |
Universal Health Services
UHS
|
+$15.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 90.32% |
| 2 | Financials | 3.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Sanofi
SNY
$105B
| $54.8M | 14.17% |
1,434,600
+331,300
| +30% | +$13.3M |
|
2
Eli Lilly
LLY
$1.02T
| $34.9M | 9.02% |
434,500
-167,300
| -28% | -$13.4M |
|
3
Elevance Health
ELV
$82.9B
| $27.5M | 7.1% |
219,200
+75,400
| +52% | +$9.74M |
|
|
SHPG
4
DELISTED
Shire pic
SHPG
| $26.7M | 6.91% |
137,900
-25,300
| -16% | -$4.94M |
|
|
ESRX
5
DELISTED
Express Scripts Holding Company
ESRX
| $21M | 5.43% |
+297,700
| New | +$22.3M |
|
|
AET
6
DELISTED
Aetna Inc
AET
| $14.3M | 3.69% |
123,600
-39,100
| -24% | -$4.58M |
|
|
ELGX
7
DELISTED
Endologix Inc
ELGX
| $13.9M | 3.6% |
108,770
+27,790
| +34% | +$3.56M |
|
8
Enanta Pharmaceuticals
ENTA
$383M
| $13.5M | 3.49% |
506,900
+24,900
| +5% | +$578K |
|
|
AGN
9
DELISTED
Allergan plc
AGN
| $13.5M | 3.48% |
+58,500
| New | +$14.3M |
|
|
10
MiMedx Group
MDXG
$645M
| $13.2M | 3.41% |
+1,538,456
| New | +$12.2M |
|
11
Bausch Health
BHC
$1.75B
| $12M | 3.1% |
488,900
+323,500
| +196% | +$8.37M |
|
|
MNTA
12
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $11.2M | 2.91% |
962,098
+153,900
| +19% | +$1.81M |
|
13
Travere Therapeutics
TVTX
$5.16B
| $10.5M | 2.72% |
470,789
+141,300
| +43% | +$2.69M |
|
14
Molina Healthcare
MOH
$12B
| $10.5M | 2.71% |
179,700
+29,000
| +19% | +$1.6M |
|
|
15
Viatris
VTRS
$19.8B
| $10.4M | 2.7% |
+273,500
| New | +$12.2M |
|
|
ALDR
16
DELISTED
Alder Biopharmaceuticals
ALDR
| $9.72M | 2.51% |
296,670
-42,400
| -13% | -$1.29M |
|
|
CORI
17
DELISTED
Corium International, Inc.
CORI
| $9.03M | 2.33% |
1,603,066
-133,400
| -8% | -$671K |
|
18
Insmed
INSM
$23.2B
| $8.62M | 2.23% |
593,336
-195,600
| -25% | -$2.45M |
|
|
TSRO
19
DELISTED
TESARO, Inc.
TSRO
| $8.45M | 2.18% |
84,300
-10,000
| -11% | -$934K |
|
|
ADPT
20
DELISTED
Adeptus Health Inc
ADPT
| $7.05M | 1.82% |
+163,700
| New | +$7.39M |
|
21
Halozyme
HALO
$9.14B
| $6.65M | 1.72% |
550,544
-235,200
| -30% | -$2.4M |
|
|
CNCE
22
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $5.79M | 1.5% |
572,388
-228,400
| -29% | -$2.5M |
|
|
FOMX
23
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $4.85M | 1.25% |
523,397
-75,000
| -13% | -$627K |
|
|
ARRY
24
DELISTED
Array Biopharma Inc
ARRY
| $4.23M | 1.09% |
+627,100
| New | +$2.43M |
|
|
ACOR
25
DELISTED
Acorda Therapeutics
ACOR
| $4M | 1.03% |
1,596
-1,389
| -47% | -$4.14M |
|
Similar funds
BCP
PRHC
NAM
GG
SM
BC
SCPM
FAM
Senzar Asset Management's Q3 2016 Portfolio in Review
As of Q3 2016, Senzar Asset Management held 49 positions worth $387M, down 16% from $459M the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Senzar Asset Management withdrew a net $92.9M in Q3 2016, closing 14 positions and reducing 19 holdings. Its most notable exit was Abbott, an estimated $30.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 90% a quarter earlier, followed by Financials.
Against the trend, Senzar Asset Management opened a new position in Express Scripts Holding Company worth $21M.
- Senzar Asset Management's largest Q3 2016 buy was Express Scripts Holding Company: 297,700 shares worth $21M.
- Senzar Asset Management added most to Sanofi in Q3 2016, an estimated $13.3M increase.
- Senzar Asset Management's biggest Q3 2016 reduction was Eli Lilly, cutting an estimated $13.4M.
- Senzar Asset Management fully exited Abbott in Q3 2016, selling an estimated $30.6M.
- Senzar Asset Management's ten largest holdings make up 60% of its $387M portfolio in Q3 2016.
- Senzar Asset Management opened 8 new positions and closed 14 in Q3 2016.
- Senzar Asset Management's portfolio value fell 16% quarter-over-quarter to $387M.
Based on Senzar Asset Management's 13F filing for Q3 2016, filed 14 Nov 2016.